BTK and B-cell chronic lymphocytic leukemia: This stimulated development of ‘non-covalent’ BTKi’s, such as pirtobrutinib or nemtabrutinib, which may be effective in treating patients with CLL cells that harbor the BTK C481S mutation [4].